Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study

The complement 5a receptor has been an attractive therapeutic target for many autoimmune and inflammatory disorders. However, development of a selective and potent C5aR antagonist has been challenging. Here we describe the characterization of CCX168 (avacopan), an orally administered selective and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekker, Pirow, Dairaghi, Daniel, Seitz, Lisa, Leleti, Manmohan, Wang, Yu, Ertl, Linda, Baumgart, Trageen, Shugarts, Sarah, Lohr, Lisa, Dang, Ton, Miao, Shichang, Zeng, Yibin, Fan, Pingchen, Zhang, Penglie, Johnson, Daniel, Powers, Jay, Jaen, Juan, Charo, Israel, Schall, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074546/
https://www.ncbi.nlm.nih.gov/pubmed/27768695
http://dx.doi.org/10.1371/journal.pone.0164646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074546/
https://www.ncbi.nlm.nih.gov/pubmed/27768695
http://dx.doi.org/10.1371/journal.pone.0164646

Ejemplares similares